Name: Ofer Mandelboim

Title： PI

Email: oferm@ekmd.huji.ac.il

Tel: +97226757515

Research Interests

Our lab focuses of the natural killer cell, part of the innate immune system. We research these cells in both humans and mice, from molecular biology all the way to clinical application, including drug development.

Natural killer cells are an important part of our immunosurveillance system, so their ability to recognize and kill cancerous cells is of particular interest. Work in our lab has investigated the effect of immunoediting by NK cells, and we recently showed that an NK activating receptor, NKp46, influences FN1 expression by tumors, ultimately affecting metastatic ability (Glasner et al. Immunity 2018). We have also discovered immune-evasion properties of oncogenes, helping to understand the clinical importance of these mutations (Elias et al. Blood 2014). Our understanding of inhibitory receptors on NK cells has even allowed us to generate novel checkpoint inhibitors, including one which is currently in pre-clinical development (NectinTX).

Ten Selected Papers

*co-corresponding authors; #co-first authors

PUBLICATIONS

Total number of papers in peer-reviewed journals is more than 200, cited more than 15,000 times. The h-index is 63.

Selected Publications (7 selected)

1. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, and Porgador A. 2001. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human natural killer cells. Nature.  409: 1055-1060.

2. Hanna J, Goldman Wohl D, Greenfield C, Nathanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, Porgador A, Keshet E Yagel S, Mandelboim O. 2006. Decidual NK Cells Regulate Key Developmental Processes at the Human Maternal-Fetal Interface. Nature Medicine. 12: 1065-1074.

3. Stern-Ginossar N, Elefant N, Zimmermann A, Wolf D, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Gabriele Hahn, Goldman-Wohl D, Greenfield C, Yagel S(CO), Hengel H, Altuvia Y, Margalit H, Mandelboim O. 2007. Host immune system gene targeting by a viral miRNA. Science. 317: 376-381.

4. Stern-Ginossar N, Gur C, Biton M , Horwitz E, Elboim M, Stanietskey N, Mandelboim M, Mandelboim O. 2008. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nature Immunology, 9: 1065-1073.

5. Gur C, Ibrahim Y, Isaacson B, Yamin R, Jawad A, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kaynan N, Coppenhagen-Glazer S, Shussman N, Almogy G, Cuapio A, Hofer E, Mevorach D, Tabib A, Ortenberg R, Markel G, Miklić K, Jonjic S, Brennan C, Garrett W, Bachrach G and Mandelboim O. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity, 2015 Feb 17;42(2):344-55.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman

6. T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O. NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 2018 Jan 16;48(1):107-119.e4.

7. Gamliel M, Goldman-Wohl D, Isaacson B, Gur C, Stein N, Yamin R, Berger M, Grunewald M, Keshet E, Rais Y, Bornstein C, David E, Jelinski A, Eisenberg I, Greenfield C, Ben-David A, Imbar T, Gilad R, Haimov-Kochman R, Mankuta D, Elami-Suzin M, Amit I, Hanna JH, Yagel S, Mandelboim O. Trained Memory of Human Uterine NK Cells Enhances Their Function in Subsequent Pregnancies. Immunity. 2018 May 15;48(5):951-962.e5.

8. Berhani O, Glasner A, Kahlon S, Duev-Cohen A, Yamin R, Horwitz E, Enk J,Moshel O, Varvak A, Porgador A, Jonjic S, Mandelboim O. Human anti-NKp46 antibody for studies of NKp46-dependent NK cell function and its applications for type 1 diabetes and cancer research. Eur J Immunol. 2019 Feb;49(2):228-241.

9. Gur C, Maalouf N, Shhadeh A, Berhani O, Singer BB, Bachrach G, Mandelboim O. <i>Fusobacterium nucleatum</i> supresses anti-tumor immunity by activating CEACAM1. Oncoimmunology. 2019 Mar 27;8(6):e1581531.

10. Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Charpak Amikam Y, Elnekave A, Tsukerman P, Kucan Brlic P, Lenac T, Seliger B, Jonjic S, Mandelboim O. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. J Immunother Cancer. 2020 Jun;8(1):e000266.